Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical, Inc. (NYSE: GMED) is a global musculoskeletal company in the surgical and medical instrument manufacturing industry. The GMED news page on Stock Titan aggregates coverage focused on the company’s musculoskeletal solutions, enabling technologies, and corporate developments that matter to investors and healthcare professionals.
News about Globus Medical often centers on quarterly and annual financial results, where the company reports worldwide net sales, U.S. and international performance, and non-GAAP metrics such as adjusted EBITDA, non-GAAP net income, and non-GAAP diluted earnings per share. These releases also discuss trends in its U.S. Spine business, contributions from acquisitions such as NuVasive and Nevro, and updates to revenue and earnings guidance.
Product and technology announcements are another key news category. Globus Medical has highlighted launches like the ANTHEM™ Elbow Fracture System within its trauma portfolio and additions to its Power Portfolio, including the DuraPro™ oscillating system with navigation and the Verzera™ high-speed drill system, which integrate with platforms such as ExcelsiusGPS™ and ExcelsiusHub™. These updates provide insight into the company’s efforts to advance spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies.
Investors can also follow corporate and legal developments, including leadership transitions at the executive level, share repurchase authorizations, and patent litigation outcomes related to expandable spinal fusion implants and other technologies. Earnings call schedules and webcast details are regularly announced, giving context on how management views business performance and strategic priorities.
By monitoring GMED news, readers can track how Globus Medical’s financial results, product pipeline, acquisitions, and intellectual property strategy evolve over time. Bookmark this page to access an organized stream of company-specific headlines and updates.
Globus Medical, Inc. (NYSE: GMED) reported its first quarter financial results for 2020, achieving worldwide sales of $190.6 million, a 4.2% increase from Q1 2019. Net income dropped to $25.9 million, representing a 21.9% decrease year-over-year. Diluted EPS stood at $0.25, down from $0.33 in Q1 2019. The company predicts a $20 million negative sales impact due to COVID-19, leading to the withdrawal of its 2020 guidance. Despite the challenges, Globus Medical launched five new products and ended the quarter with $657.0 million in cash and equivalents.